Kuwayama H et al. |
Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17439512
|
Wong WM et al. |
Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15644048
|
Van Oijen AH et al. |
Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930892
|
Hurenkamp GJ et al. |
Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930901
|
Wheeldon TU et al. |
Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12848630
|
Lai KC et al. |
Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930902
|
Pilotto A et al. |
Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930903
|
Kihira K et al. |
Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930904
|
Kamada T et al. |
Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930905
|
Dalla Libera M et al. |
High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8730251
|
Labenz J et al. |
One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8730252
|
Gatta L et al. |
A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15963079
|
Nseir W et al. |
Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22646167
|
Wong BC et al. |
Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11380322
|
Meier R et al. |
Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11380323
|
Gisbert JP and Calvet X |
Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22129228
|
Hokari K et al. |
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11552922
|
Kamberoglou D et al. |
Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11552924
|
Harris A |
The importance of clarithromycin dose in the management of H. pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10594406
|
Harb AH et al. |
Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:26011564
|
al-Assi MT et al. |
Clarithromycin-amoxycillin therapy for Helicobacter pylori infection. |
1994 |
Aliment. Pharmacol. Ther. |
pmid:7986970
|
Spinzi G et al. |
Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9146769
|
Peterson WL |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9146787
|
Nada T et al. |
DNA typing for Helicobacter pylori isolates from eradication-failed patients: comparison of the isolates before and after therapy. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298604
|
Kaneko F et al. |
High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298607
|
Sierra F et al. |
Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23656465
|
Masaoka T et al. |
Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298608
|
Okudaira K et al. |
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15710002
|
Kondo Y et al. |
Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298609
|
Lai KC et al. |
Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12641502
|
Zullo A et al. |
High eradication rates of Helicobacter pylori with a new sequential treatment. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12641522
|
Chiba N et al. |
Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:14984382
|
de Francesco V et al. |
Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16423002
|
Di Mario F et al. |
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16611285
|
Madisch A et al. |
Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16441467
|
Borody TJ et al. |
Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16441468
|
Veldhuyzen Van Zanten S et al. |
One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12786632
|
Wong BC et al. |
Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10651663
|
Fock KM et al. |
Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10651664
|
Wong BC et al. |
One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207516
|
Fakheri H et al. |
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207517
|
Lamouliatte H et al. |
Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10571611
|
Nagahara A et al. |
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207518
|
Bardhan KD et al. |
Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632646
|
Cammarota G et al. |
Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632648
|
Fischbach LA et al. |
Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15569109
|
Katelaris PH et al. |
A randomized prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori. |
1995 |
Aliment. Pharmacol. Ther. |
pmid:7605864
|
Yousfi MM et al. |
Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. |
1995 |
Aliment. Pharmacol. Ther. |
pmid:7605865
|
Axon AT et al. |
Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042977
|
Choi IJ et al. |
Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11856089
|
Bazzoli F et al. |
Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11856090
|
Park HG et al. |
Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22066530
|
Kim JS et al. |
Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860410
|
Malfertheiner P et al. |
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860399
|
Poon SK et al. |
Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860412
|
Peitz U et al. |
High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860415
|
Barth J and Hahne W |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11849125
|
Qasim A and O'Morain CA |
Review article: treatment of Helicobacter pylori infection and factors influencing eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11849124
|
Sheu BS et al. |
Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12197847
|
Sieg A et al. |
Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383519
|
Calvet X et al. |
One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12144575
|
Cestari R |
Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9798804
|
Grimley CE et al. |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383520
|
Spadaccini A et al. |
Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9798805
|
Houben MH et al. |
Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383522
|
Bortolotti M et al. |
Effects of oral clarithromycin and amoxycillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9798808
|
Calvet X et al. |
A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10792124
|
John Albert M et al. |
High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:17059517
|
Spinzi GC et al. |
Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663722
|
Villoria A et al. |
Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18644011
|
O'Connor HJ et al. |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9570262
|
Scott BB |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9570263
|
Goodgame RW et al. |
Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11736715
|
Malfertheiner P et al. |
Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12752349
|
Gené E et al. |
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12752350
|
Veldhuyzen Van Zanten S et al. |
One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11121908
|
Isomoto H et al. |
5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11121910
|
Canducci F et al. |
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11121911
|
Toracchio S et al. |
Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11121913
|
Cammarota G et al. |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971300
|
Pilotto A et al. |
Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971305
|
Gisbert JP et al. |
Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16556172
|
Tam YH et al. |
Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16803605
|
Kawabata H et al. |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12534411
|
Gisbert JP et al. |
Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11012477
|
Catalano F et al. |
Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11012478
|
Gomollón F et al. |
Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11012479
|
Mason JM et al. |
Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18793340
|
Fraser AG |
Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28776748
|
Jung YS et al. |
Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28776746
|
Nista EC et al. |
Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12969089
|
De Francesco V et al. |
Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:14871280
|
Tankovic J et al. |
Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11328266
|
Koivisto TT et al. |
First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15771764
|
Klok RM et al. |
Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966514
|
Coelho LG et al. |
Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12492742
|
Tursi A et al. |
Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8791952
|
Feydt-Schmidt A et al. |
Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12452940
|
Isomoto H et al. |
High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12848631
|
Ellenrieder V et al. |
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9701524
|